Drugs / Zotatifin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07783659 | Feb 2027 → Jun 2030 expected | triple-negative breast carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04092673 | Oct 2019 → Dec 2024 | cancer | Effector Therapeutics | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05101564 | Mar 2023 → Jun 2024 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Jennifer Lee Caswell-Jin | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04632381 Comparator | Jul 2021 → Jan 2023 | COVID-19 | Effector Therapeutics | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zotatifin | “Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies” NCT04092673 ↗ |
| Known as | eFT226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04092673 ↗ |
| Known as | Zotatifina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303782 ↗ |
| Known as | Zotatifine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303782 ↗ |
| Action | Inhibit | “eIF4A1 inhibition by eFT226” NCT04092673 ↗ |
| Modality | Small molecule | “eFT226 is a novel small-molecule, investigational drug” NCT04092673 ↗ |
| Route | Intravenous | “eFT226 administered IV weekly in 21-day cycles” NCT04092673 ↗ |
| Target | EIF4A1 | “eIF4A1 inhibition by eFT226 downregulates expression” NCT04092673 ↗ |